Business
Tandem Diabetes Care Acquires Infusion Set Developer, Capillary Biomedical
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced its
About this update from Tandem Diabetes Care, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nTandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced its acquisition of infusion set developer, Capillary Biomedical.\n\n“Infusion sets provide people flexible options in insulin pump wearability, and we are dedicated to expanding our portfolio of sets to offer our customers even greater choice in personalizing their therapy management system,” said John Sheridan, Tandem Diabetes Care president and chief executive officer. “Through this acquisition, and through our efforts with existing infusion set partners, we look forward to developing new and innovative infusion set solutions that are designed to extend wear time and enhance user experience, while reducing occlusions, body burden and waste.”\n\nCapillary Biomedical’s unique extended wear infusion set technology is currently in development and not commercially available. Financial terms were not disclosed.\n\nAbout Tandem Diabetes Care, Inc.\n\nTandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.\n\nFollow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and $TNDM.\nFollow Tandem Diabetes Care on Facebook at facebook.com/TandemDiabetes.\nFollow Tandem Diabetes Care on LinkedIn at linkedin.com/company/tandemdiabetes.\n\n© 2022 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Control-IQ, and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.\n\nForward Looking Statements\n\nThis press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties...